Современное состояние проблемы диагностики гепатоцеллюлярного рака
Аннотация
Цель обзора. Представить особенности диагностики гепатоцеллюлярного рака (ГЦР).
Основные положения. Рассмотрены факторы развития ГЦР, принципы проведения скрининга в группе риска. Описана роль ультразвукового исследования, рентгеновской, компьютерной и магнитно-резонансной томографии в диагностике ГЦР, а также отражены дополнительные сведения, которые можно получить с помощью лучевых методов исследования, что имеет огромное значение в определении резектабельности и предоперационном планировании хирургического вмешательства. Описана лучевая диагностика при сопутствующем циррозе, сложность обнаружения ГЦР малых размеров. Лучевую дифференциальную диагностику ГЦР следует проводить с диспластическими узелками. Рассмотрены преимущества и ограничения каждого из методов визуализации.
Заключение. Проблема диагностики гепатоцеллюлярного рака продолжает оставаться актуальной и требует проведения дальнейших исследований.
Об авторах
Т. Ю. Данзанова
НИИ клинической онкологии ФГБУ «РОНЦ им. Н.Н. Блохина» РАН
Россия
Россия
Данзанова Татьяна Юрьевна – кандидат медицинских наук, старший научный сотрудник, отделение ультразвуковой диагностики отдела лучевой диагностики и интервенционной радиологии
115478, Москва, Каширское шоссе, д. 24
Г. Т. Синюкова
НИИ клинической онкологии ФГБУ «РОНЦ им. Н.Н. Блохина» РАН
Россия
Россия
Синюкова Галина Тимофеевна – доктор медицинских наук, профессор, заведующая, отделение ультразвуковой диагностики отдела лучевой диагностики и интервенционной радиологии
П. И. Лепэдату
НИИ клинической онкологии ФГБУ «РОНЦ им. Н.Н. Блохина» РАН
Россия
Россия
Лепэдату Павел Иванович – кандидат медицинских наук, старший научный сотрудник, отделение ультразвуковой диагностики отдела лучевой диагностики и интервенционной радиологии
Список литературы
1. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей. М.: ГЭОТАР; 1999:75-7, 603-733.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer
3. ; 94(2):153-6.
4. Tinkle C.L., Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012; 6:207-19.
5. Marrero J.A., Welling T. Modern diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2009
6. May; 13(2):233-47.
7. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. / Под ред. М.И. Давыдова, Е.М. Аксель. М.: Вестник РОНЦ им. Н.Н. Блохина РАМН 2009; 20(3):12-64.
8. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003; 362(9399):1907-17.
9. Colombo M. Risk groups and preventive strategies. In: F. Berr, J. Bruix, J. Hauss, .J Wands, C. Wittekind, et al., eds. Malignant liver tumors: basic concepts and clinical management. Falk symposium: Kluwer Academic Publishers; 2003:67-74.
10. Willatt J.M., Hussain H.K., Adusumilli S., Marrero J.A. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008 May; 247(2):311-30.
11. Bosch F.X., Ribes J., Díaz M., Clèries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(5 suppl. 1):5-16.
12. Coleman W.B. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003; 3(6):573-88.
13. Efremidis S.C., Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol 2002; 12(4):753-64.
14. Llovet J.M., Schwartz M., Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25(2):181-200.
15. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., Christensen E., Pagliaro L., Colombo M., Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-30.
16. Gannon C.J., Izzo F., Aloia T.A., Pignata S., Nasti G., Vallone P., Orlando R., Scordino F., Curley S.A. Can hepatocellular cancer screening increase the proportion of long-term survivors? Hepatogastroenterology 2009 JulAug; 56(93):1152-6.
17. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004 Jul; 130(7):417-22.
18. Parvez T., Parvez B., Pervaiz K., Gumgumji A.A., Al Ahmadi S., Sabir A.A., Khawaja F.I. Screening for hepa tocellular carcinoma. J Coll Physicians Surg Pak 2004 Sep; 14(9):570-5.
19. Daniele B., Bencivenga A., Megna A.S., Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004 Nov; 127(5 suppl. 1):108-12.
20. Paul S.B., Gulati M.S., Sreenivas V., Madan K., Gupta A.K., Mukhopadhyay S., Acharya. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology 2007; 72, suppl. 1:117-23.
21. Gomaa A.I., Khan S.A., Toledano M.B., Waked I., Taylor-Robinson S.D. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14:4300-8.
22. Torzilli G., Minagawa M., Takayama T., Inoue K., Hui A.M., Kubota K., Ohtomo K., Makuuchi M. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999; 30:889-93.
23. Robinson P. Hepatocellular carcinoma: development and early detection. Cancer Imaging 2008 Oct 4; 8 Spec No A:128-31.
24. Bolondi L., Gaiani S., Celli N., Golfieri R., Grigioni W.F., Leoni S., Venturi A.M., Piscaglia F. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005 Jul; 42(1):27-34.
25. Ryder S.D. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52, suppl. 3:1-8.
26. Roncalli M., Roz E., Coggi G., Di Rocco M.G., Bossi P., Minola E., Gambacorta M., Borzio M. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999; 30:1174-8.
27. Tanaka S., Kitamura T., Fujita M., Nakanishi K., Okuda S. Color Doppler flow imaging of liver tumors. AJR Am J Roentgenol 1990 Mar; 154(3):509-14.
28. Hsu C., Chen C.N., Chen L.T., Wu C.Y., Hsieh F.J., Cheng A.L. Effect of thalidomide in hepatocellular carci noma: assessment with power doppler US and analysis of circulating angiogenic factors. Radiology 2005 May;
29. (2):509-16.
30. Kono Y., Steinbach G.C., Peterson T., Schmid-Schonbein G.W., Mattrey R.F. Mechanism of parenchymal enhancement of the liver with a microbubble-based US contrast medium: an intravital microscopy study in rats. Radiology 2002; 224:253-7.
31. Yanagisawa K., Moriyasu F., Miyahara T., Yuki M., Iijima H. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 2007; 33:318-25.
32. Nicolau C., Bru C. Characterisation of hepatocellular carcinoma in cirrhosis. In: R Lencioni, et al., eds. Enhancing the role of ultrasound with ultrasound contrast agents. Pisa: Springer; 2006:39-52.
33. Nicolau C., Vilana R., Catala V., Bianchi L., Gilabert R., Garcia A., Bru C. Importance of evaluating all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions. AJR Am J Roentgenol 2006; 186:158-67.
34. Kudo M., Hatanaka K., Inoue T., Maekawa K. Depiction of portal supply in early hepatocellular carcinoma and dysplastic nodule: value of pure arterial ultrasound imaging in hepatocellular carcinoma. Oncology 2010 Jul; 78, suppl. 1:60-7.
35. Lencioni R., Della Pina C., Crocetti L., Bozzi E., Cioni D. Clinical management of focal liver lesions: the key role of real-time contrast-enhanced US. Eur Radiol 2007 Dec; 17, suppl. 6:73-9.
36. Inoue T., Kudo M., Hatanaka K., Takahashi S., Kitai S., Ueda T., Ishikawa E., Hagiwara S., Minami Y., Chung H., Ueshima K., Maekawa K. Imaging of hepatocellular carcinoma: qualitative and quantitative analysis ofpostvascular phase contrastenhanced ultrasonography with sonazoid. Comparison with superparamagnetic iron oxide magnetic resonance images. Oncology 2008; 75, suppl. 1:48-54.
37. Lemke A.J., Chopra S.S., Hengst S.A., Brinkmann M.J., SteinmГјller T., Felix R. Characterization of hepatic tumors with contrast-enhanced ultrasound and digital grey-scale analysis. Rofo 2004 Nov; 176(11):1607-16.
38. Kudo M., Tochio H. Intranodular blood supply correlates well with biological malignancy grade determined by tumor growth rate in pathologically proven hepatocellular carcinoma. Oncology 2008; 75, suppl. 1:55-64.
39. Bartolozzi C., Crocetti L., Della Pina M.C. How to differentiate liver lesions in cirrhosis. JBR-BTR 2007 NovDec; 90(6):475-81.
40. Lencioni R., Piscaglia F., Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008 May; 48(5):848-57.
41. Sontum P.C. Physicochemical characteristics of Sonazoid, a new contrast agent for ultrasound imaging. Ultrasound Med Biol 2008; 34:824-33.
42. Dohmen T., Kataoka E., Yamada I., Miura K., Ohshima S., Shibuya T., Segawa D., Sato W., Anezaki Y., Ishii H., Kamada K., Goto T., Ohnishi H. Efficacy of contrast-enhanced ultrasonography in radiofrequency ablation for hepatocellular carcinoma. Intern Med 2012; 51(1):1-7.
43. Luo W., Numata K., Morimoto M., Nozaki A., Ueda M., Kondo M., Morita S., Tanaka K. Differentiation of focal liver lesions using three-dimensional ultrasonography: Retrospective and prospective studies. World J Gastroenterol 2010 May 7; 16(17):2109-19.
44. Gheorghe L., Iacob S., Iacob R., Dumbrava M., Becheanu G., Herlea V., Gheorghe C.,Lupescu I., Popescu I. Real time elastography a non-invasive diagnostic method of small hepatocellular carcinoma in cirrhosis. J Gastrointestin Liver Dis 2009 Dec; 18(4):439-46.
45. Choi B.I. Advances of imaging for hepatocellular carcinoma. Oncology 2010 Jul; 78, suppl. 1:46-52.
46. Weg N., Scheer M.R., Gabor MP. Liver lesions: improved detection with dual-detector-array CT and routine 2.5-mm thin collimation. Radiology 1998; 209:417-26.
47. Baron R.L., Oliver JH 3rd, Dodd GD 3rd, Nalesnik M., Holbert B.L., Carr B. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996; 199:505-11.
48. Brancatelli G., Federle M.P., Grazioli L., Carr B.I. Hepatocellular carcinoma in noncirrhotic liver: C.T., clinical, and pathologic findings in 39 U.S. residents. Radiology 2002; 222:89-94.
49. Iannaccone R., Piacentini F., Murakami T., Paradis V., Belghiti J., Hori M., Kim T., Durand F., Wakasa K., Monden M., Nakamura H., Passariello R., Vilgrain V. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology 2007; 243:422-30.
50. Tublin M.E., Dodd G.D. 3rd, Baron R.L. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol 1997; 168:719-23.
51. Glockner J.F. Hepatobiliary MRI: current concepts and controversies. J Magn Reson Imaging 2007; 25:681-95.
52. Teefey S.A., Hildeboldt C.C., Dehdashti F., Siegel B.A., Peters M.G., Heiken J.P., Brown J.J., McFarland E.G., Middleton W.D., Balfe D.M., Ritter J.H. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of C.T., MR imaging, U.S., and PET. Radiology 2003; 226:533-42.
53. Semelka R.C., Helmberger T.K. Contrast agents for MR imaging of the liver. Radiology 2001; 218:27-38.
54. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol 2006; 60:314-23.
55. Gandhi S.N., Brown M.A., Wong J.G., Aguirre D.A., Sirlin C.B. MR contrast agents for liver imaging: what, when, how. Radiographics 2006; 26:1621-36.
56. Ariff B., Lloyd C.R., Khan S., Shariff M., Thillainayagam A.V., Bansi D.S., Khan S.A., Taylor-Robinson S.D., Lim A.K. Imaging of liver cancer. World J Gastroenterol 2009; 15:1289-300.
57. Kudo M. Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology 2011; 81, suppl. 1:73-85.
58. Murakami T., Imai Y., Okada M., Hyodo T., Lee W.J., Kim M.J., Kim T., Choi B.I. Ultrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: toward improved treatment decisions. Oncology 2011; 81, suppl. 1:86-99.
59. Chow L.C., Bammer R., Moseley M.E., Sommer F.G. Single breath-hold diffusion-weighted imaging of the abdomen. J Magn Reson Imaging 2003; 18:377-82.
60. Namimoto T., Yamashita Y., Sumi S., Tang Y., Takahashi M. Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 1997; 204:739-44.
61. Taouli B., Vilgrain V., Dumont E., Daire J.L., Fan B., Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two singleshot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003; 226:71-8.
62. Meikle S.R., Dahlbom M. Positron emission tomography (PET). In: PJ Ell, SS Gambhir, eds. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone; 2004:1827-43.
63. Choi B.Y., Nguyen M.H. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol 2005; 39:401-12.
64. Blechacz B., Gores G.J. Positron emission tomography scan for a hepatic mass. Hepatology 2010 Dec; 52(6):2186-91.
65. Trojan J., Schroeder O., Raedle J., Baum R.P., Herrmann G., Jacobi V., Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94:3314-9.
66. Khan M.A., Combs C.S., Brunt E.M., Lowe V.J., Wolverson M.K., Solomon H., Collins B.T., di Bisceglie A.M. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32:792-7.
67. Park J.W., Kim J.H., Kim S.K., Kang K.W., Park K.W., Choi J.I., Lee W.J., Kim C.M., Nam B.H. A prospective evaluation of 18F-FDG and 11C-acetate PET/ CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008; 49:1912-21.
68. Ho C.L., Yu S.C., Yeung D.W. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44:213-21.
69. Ayyappan A.P., Jhaveri K.S. CT and MRI of hepatocellular carcinoma: an update // Expert Rev Anticancer Ther. 2010 Apr;10(4):507-19.
70. Mita K., Kim S.R., Kudo M., Imoto S., Nakajima T., Ando K., Fukuda K., Matsuoka T., Maekawa Y., Hayashi Y. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2010 Sep 7; 16(33):4187-92.
71. Khan S.A., Davidson B.R., Goldin R., Pereira S.P., Rosenberg W.M., Taylor-Robinson S.D., Thillainayagam A.V., Thomas H.C., Thursz M.R., Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51, suppl. 6:1-9.
72. Colombo M., de Franchis R., del Ninno E., Sangiovanni A., de Fazio C., Tommasini M., Donato M.F., Piva A., di Carlo V., Dioguardi N. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675-80.
73. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986; 6:729-38.
74. Vilana R., Llovet J.M., Bianchi L., Sanchez M., Pagés M., Sala M., Gilabert R., Nicolau C., Garcia A., Ayuso C., Bruix J., Bru C. Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound 2003; 31:119-28.
75. Giorgio A., Ferraioli G., Tarantino L., de Stefano G., Scala V., Scarano F., Coppola C., del Viscovo L. Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol 2004; 183:1319-26.
76. Gaiani S., Celli N., Piscaglia F., Cecilioni L., Losinno F., Giangregorio F., Mancini M., Pini P., Fornari F., Bolondi L. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 2004; 41:421-6.
77. Fracanzani A.L., Burdick L., Borzio M., Roncalli M., Bonelli N., Borzio F., Maraschi A., Fiorelli G., Far gion S. Contrast-enhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology 2001; 34:1109-12.
78. Peterson M.S., Baron R.L., Marsh JW Jr, Oliver J.H 3rd, Confer S.R., Hunt L.E. Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology 2000; 217:743-9.
79. Hussain S.M., Zondervan P.E., IJzermans J.N., Schalm S.W., de Man R.A., Krestin G.P. Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 2002; 22:1023-36; discussion 1037-9.
80. Jeong Y.Y., Yim N.Y., Kang H.K. Hepatocellular carcinoma in the cirrhotic liver with helical CT and MRI: imaging spectrum and pitfalls of cirrhosis-related nodules // AJR Am J Roentgenol 2005; 185:1024-32.
81. Goshima S., Kanematsu M., Matsuo M., Kondo H., Yokoyama R., Hoshi H., Moriyama N. Early-enhancing nonneoplastic lesions on gadolinium-enhanced magnetic resonance imaging of the liver following partial hepatectomy. J Magn Reson Imaging 2004; 20:66-74.
82. Jeong Y.Y., Mitchell D.G., Kamishima T. Small (<20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications. AJR Am J Roentgenol 2002; 178:1327-34.
83. Yoo H.J., Lee J.M., Lee J.Y., Kim S.H., Kim S.J., Han J.K., Choi B.I. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver. Invest Radiol 2009 Dec; 44(12):800-7.
84. Colli A., Fraquelli M., Casazza G., Massironi S., Colucci A., Conte D., Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101(3):513-23.
85. Kondo H., Kanematsu M., Hoshi H., Murakami T., Kim T., Hori M., Matsuo M., Nakamura H. Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT. AJR Am J Roentgenol 2000; 174:947-54.
86. Krinsky G.A., Lee V.S., Theise N.D., Weinreb J.C., Morgan G.R., Diflo T., John D., Teperman L.W., Goldenberg A.S. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl 2002; 8(12):1156-64.
87. Burrel M., Llovet J.M., Ayuso C., Iglesias C., Sala M., Miquel R., Caralt T., Ayuso J.R., Solé M., Sanchez M., Brú C., Bruix J. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38(4):1034-42.
88. Noguchi Y., Murakami T., Kim T., Hori M., Osuga K., Kawata S., Kumano S., Okada A., Sugiura T., Nakamura H. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR Am J Roentgenol 2003; 180(2):455-60.
89. Krinsky G.A., Lee V.S., Theise N.D., Weinreb J.C., Rofsky N.M., Diflo T., Teperman L.W. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001; 219(2):445-54.
90. Tomemori T., Yamakado K., Nakatsuka A., Sakuma H., Matsumura K., Takeda K. Fast 3D dynamic MR imaging of the liver with MR SmartPrep: comparison with helical CT in detecting hypervascular hepatocellular carcinoma. Clin Imaging 2001; 25(5):355-61.
91. Libbrecht L., Bielen D., Verslype C., Vanbeckevoort D., Pirenne J., Nevens F., Desmet V., Roskams T. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8(9):749-61.
92. De Lédinghen V., Laharie D., Lecesne R., Le Bail B., Winnock M., Bernard P.H., Saric J., Couzigou P., Balabaud C., Bioulac-Sage P., Drouillard J. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? a prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002; 14(2):159-65.
93. Rode A., Bancel B., Douek P., Chevallier M., Vilgrain V., Picaud G., Henry L., Berger F., Bizollon T., Gaudin J.L., Ducerf C. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examinatin of explanted liver. J Comput Assist Tomogr 2001; 25(3):327-36.
94. Noguchi Y., Murakami T., Kim T., Hori M., Osuga K., Kawata S., Okada A., Sugiura T., Tomoda K., Narumi Y., Nakamura H. Detection of hypervascular hepatocellular carcinoma by dynamic magnetic resonance imaging with double-echo chemical shift in-phase and opposed-phase gradient echo technique: comparison with dynamic helical computed tomography imaging with double arterial phase. J Comput Assist Tomogr 2002; 26(6):981-7.
95. Sangiovanni A., Manini M.A., Iavarone M., Romeo R., Forzenigo L.V., Fraquelli M., Massironi S., Della Corte C., Ronchi G., Rumi M.G., Biondetti P., Colombo M. The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010 May; 59(5):638-44.
Рецензия
Для цитирования:
Данзанова Т.Ю., Синюкова Г.Т., Лепэдату П.И. Современное состояние проблемы диагностики гепатоцеллюлярного рака. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;24(4):12-22.
For citation:
Danzanova T.Yu., Sinyukova G.T., Lepedatu P.I. Diagnostics of hepatocellular cancer: state-of-the-art. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(4):12-22. (In Russ.)
Просмотров:
150
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Послать статью по эл. почте 
